Study guide

23.2 Monitoring Eligibility, Safety and Products

ACRP CCRA Certified Clinical Research Associate Study Guide 2026 Exam

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Exam Format, Eligibility and Registration

1.1 Exam Format, Eligibility and Current References 1.2 Registration, Fees and Candidate Decisions

2 Chapter 2: CRA Responsibilities and Study Planning

2.1 The CRA Role, Data Integrity and Product Oversight 2.2 Official Blueprint and Study Strategy

3 Chapter 3: Protocols, Endpoints and Trial Design

3.1 Protocol Elements and Endpoint Hierarchy 3.2 Endpoint Interpretation and Eligibility Rationale 3.3 Eligibility Verification and Trial Designs

4 Chapter 4: Bias Control, Blinding and Product Information

4.1 Bias, Randomisation and Comparator Controls 4.2 Unblinding and Investigator Brochure Content 4.3 Reference Safety Information and IB Updates

5 Chapter 5: Estimands and Device Instructions

5.1 Estimands and Intercurrent Events 5.2 Device Instructions, Configuration and Training

6 Chapter 6: Ethical Foundations and Independent Oversight

6.1 Ethical Foundations and the 2024 Declaration of Helsinki 6.2 Vulnerability, Voluntariness and Compensation 6.3 IRB/IEC Composition and Independent Review

7 Chapter 7: Ethics Communication and Informed Consent

7.1 Ethics Reporting, Approval Status and Version Control 7.2 Informed Consent Information and Meaningful Choice 7.3 Consent Documentation, Special Circumstances and Updates

8 Chapter 8: Recruitment, Retention and Confidentiality

8.1 Ethical Eligibility, Recruitment and Retention 8.2 Privacy, Confidentiality and Appropriate Access

9 Chapter 9: Safety Definitions and Classification

9.1 Adverse Event Definitions and Actual Life-Threatening Risk 9.2 Seriousness, Severity and Medical Importance 9.3 Causality, Expectedness and Reference Safety Information

10 Chapter 10: Safety Detection, Reporting and Oversight

10.1 Detecting Events, AESIs and Collection Windows 10.2 Expedited Reporting and the Sponsor Awareness Clock 10.3 Immediate Site Reporting and Independent Safety Oversight

11 Chapter 11: Follow-Up, Adherence and Conflicts

11.1 Safety Communications, Reconciliation and Follow-Up 11.2 Adherence, Discontinuation and Participant Choice 11.3 Conflicts of Interest and Prorated Payments

12 Chapter 12: Development Stages and Product Management

12.1 Nonclinical Background and Human Pharmacology 12.2 Exploratory, Confirmatory and Therapeutic-Use Studies 12.3 Product Storage, Labelling and Excursion Response

13 Chapter 13: Accountability, Integrity and Regulatory Status

13.1 Product Accountability and Adherence Calculations 13.2 Potential Fraud, Misconduct and Evidence Preservation 13.3 Submissions, Authorisation Status and Trial Reporting

14 Chapter 14: Current GCP Principles and Delegation

14.1 The Eleven Current GCP Principles 14.2 Proportionality and Investigator Oversight 14.3 Delegation, Qualifications and Task Authority

15 Chapter 15: Oversight, Protocol Control and Amendments

15.1 Clinical Oversight and Immediate-Hazard Changes 15.2 Deviation Classification and Resolution

16 Chapter 16: Implementation and Trial Responsibilities

16.1 Amendment Implementation and Communication 16.2 Sponsor, Investigator and Service-Provider Roles

17 Chapter 17: Quality Planning, Root Causes and CAPA

17.1 Quality Planning and Risk Management 17.2 Root Cause Analysis and CAPA Design 17.3 CAPA Implementation and Effectiveness Verification

18 Chapter 18: Risk Assessment and Monitoring Methods

18.1 Risk Assessment and Centralised Surveillance 18.2 Monitoring Methods and Source Review

19 Chapter 19: Quality Metrics, Plans and Communication

19.1 KRIs, Acceptable Ranges and Trial-Level Quality 19.2 Monitoring Plans, Co-Monitoring and Communication

20 Chapter 20: Site Qualification and Readiness

20.1 Site Qualification and Investigator Capacity 20.2 Recruitment Feasibility and Evidence-Based Site Selection 20.3 Site Readiness and Activity-Specific Release

21 Chapter 21: Initiation, Equipment and Supplies

21.1 Initiation Training and Readiness Walkthroughs 21.2 Equipment, Maintenance and Study Supplies

22 Chapter 22: Samples, Diagnostics and Financial Feasibility

22.1 Specimens, Diagnostic Results and Rater Quality 22.2 Contracts, Budgets and Operational Feasibility

23 Chapter 23: Interim Monitoring and Reporting

23.1 Interim Visit Preparation and Consent Review 23.2 Monitoring Eligibility, Safety and Products 23.3 Investigator Debrief and Monitoring Reports

24 Chapter 24: Essential Records, Audits and Findings

24.1 Essential Records and Site/Sponsor Reconciliation 24.2 Version History, Resolution Evidence and Noncompliance 24.3 Audits, Inspections and Closure Planning

25 Chapter 25: Close-Out, Retention and Destruction

25.1 Close-Out, Archiving and Continuing Obligations 25.2 Retention, Destruction and Long-Term Access

26 Chapter 26: Source Records and Good Documentation

26.1 Source Records and Foundational ALCOA Principles 26.2 Good Documentation, Completeness and Corrections 26.3 Source Access, Certified Copies and Context

27 Chapter 27: Electronic Systems, Metadata and Queries

27.1 EDC Design and Fit-for-Purpose Systems 27.2 Audit Trails, Electronic Outcomes and Device Choice 27.3 Queries, Coding and Supported Clinical Meaning

28 Chapter 28: Dataset Finalisation and Critical Data

28.1 Safety Reconciliation and Dataset Finalisation 28.2 Critical Data, Acquisition Tools and Interim Findings

23.2 Monitoring Eligibility, Safety and Products

Key Takeaways Explain This Topic AI

Trace relevant eligibility criteria to source evidence under the monitoring plan.

Safety review includes possible unrecorded events and actual reporting routes.

Product review combines appropriate physical, documentary and clinical evidence.

Last updated: October 2026

Monitoring Eligibility, Safety and Products

Enrolling ineligible participants introduces confounding variables that compromise trial statistical power and exposes participants to unknown clinical risks.

Primary Source Triangulation: The monitor verifies eligibility according to the monitoring plan, tracing relevant criteria to source evidence. Eligibility cannot be verified from a site-generated checklist alone; the CRA must trace each criterion back to certified primary source records (e.g., histology pathology reports confirming tumor staging, baseline laboratory chemistry panels, 12-lead ECG intervals, prior medical history notes from referring institutions).

Prohibition of Protocol Waivers: Under modern GCP and regulatory standards, "protocol waivers" or retrospective eligibility exemptions granted by sponsors or medical monitors are strictly prohibited. Every subject must satisfy every protocol criterion exactly as written.

Source Data Verification (SDV) vs. Source Data Review (SDR)

A critical core competency tested on professional clinical research examinations is the conceptual and operational distinction between Source Data Verification and Source Data Review:

Operational Dimension Source Data Verification (SDV) Source Data Review (SDR)

Primary Objective Confirm data transcription fidelity and numerical accuracy between source and CRF. Evaluate protocol compliance, clinical plausibility, patient safety, and data integrity.

Core Activity Matching data points: verifying that a serum creatinine of 1.2 mg/dL 1.2\text{ mg/dL} 1.2 mg/dL in the lab report is entered as 1.2 1.2 1.2 in EDC. Reading clinical progress notes, nursing narratives, physician orders, and discharge summaries holistically.

Scope & Focus Focused on discrete data fields, data entry precision, and typographic verification. Broad clinical oversight: identifying undocumented adverse events, unrecorded concomitant medications, or subtle clinical deterioration.

Standard Method Field-by-field cross-referencing between source records and electronic Case Report Forms. Qualitative, critical clinical analysis evaluating the patient's entire medical journey during the trial.

Example Defect Detected A blood pressure reading of 138 / 88 mmHg 138/88\text{ mmHg} 138/88 mmHg was incorrectly transcribed into EDC as 183 / 88 mmHg 183/88\text{ mmHg} 183/88 mmHg . An EMR discharge summary mentions a patient was hospitalized for syncope, but no SAE was reported to the sponsor.

Tip

While SDV confirms that data were recorded accurately, SDR evaluates whether the trial was conducted safely and ethically. In modern Risk-Based Monitoring paradigms, high-performing CRAs spend less time performing routine transcription SDV and significantly more time conducting deep clinical SDR across primary medical narratives.

Safety Review and Serious Adverse Event (SAE) Reconciliation

Auditing participant safety is the monitor's paramount ethical duty:

Adverse Event Log Review: The CRA audits clinic notes, nursing communication logs, vitals sheets, and laboratory panic values to identify potential adverse events that site personnel failed to record.

Concomitant Medication Triangulation: The CRA cross-references newly prescribed or modified medications against the AE log. For example, if a participant's EMR reveals a new prescription for oral ciprofloxacin, the monitor investigates whether the site experienced and failed to report a urinary tract infection or respiratory infection as an adverse event.

Immediate SAE Escalation (ICH E2A): Under E6(R3) and the trial safety plan, Serious Adverse Events (SAEs)—defined as any untoward medical occurrence resulting in death, life-threatening condition, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability/incapacity, congenital anomaly/birth defect, or medically significant intervention—must be reported to the sponsor immediately, following the protocol and any permitted exceptions. The CRA verifies that SAE forms were transmitted immediately, that clinical details match hospital discharge summaries, that causality assessments were made by the appropriately qualified investigator/designee under applicable requirements, and that institutional IRB notification requirements were satisfied.

Investigational Product (IP) Accountability and Environmental Controls

Under ICH E6(R3), the CRA audits the physical and documented chain of custody of the investigational product:

Storage Environmental Verification: Inspect the storage conditions and monitoring records against the product-specific instructions. Investigate undocumented excursions, protect affected stock from dispensing, and obtain sponsor evaluation/disposition. A generic ambient or refrigerated range cannot clear a particular batch.

Physical Inventory Unit Counts: The CRA physically counts all unopened kits, partially used packages, and returned empty containers, comparing the physical count against the Master Drug Accountability Log (DAL) and individual Subject Dispensing Logs.

Participant adherence: Compare dispensing, returns, medical holds and participant reports using the protocol's definition. Units dispensed minus units returned estimates use, not proven ingestion. Do not assume a universal 80–120% acceptable range.

Pharmacy and Ancillary Laboratory Inspection

The CRA inspects all support facilities contributing to trial data:

Pharmacy Inspection: Verification of sterile preparation hoods, laminar flow certification dates, pharmacist training logs, access restriction (keycard/lock controls), and segregation of investigational supplies from commercial hospital stock.

Laboratory Oversight: Auditing local clinical laboratories for appropriate laboratory quality/qualification evidence under applicable requirements. The CRA collects updated normal reference ranges signed and dated by the laboratory medical director.

Biological Specimen Management: The CRA inspects − 20 ∘ C -20^\circ\text{C} − 2 0 ∘ C and − 80 ∘ C -80^\circ\text{C} − 8 0 ∘ C freezers housing pharmacokinetic (PK) and biomarker blood samples, verifying temperature logs, sample labeling, split-aliquot separation, and shipping manifests for central laboratory transport.

Official sources

Checked October 18, 2026: ICH E6(R3), Principles and Annex 1 .